Stock Ratings / Health Care / BGLC / earnings

ADVB (32) ACON (24) AMS (29) SERA (40) ⌘ Pro Terminal →

BioNexus Gene Lab Corp (BGLC) Next Earnings Date & Expected ±10.6% Move

Q: Is BGLC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BioNexus Gene Lab Corp (NASDAQ: BGLC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.98 (-7.79% 1D, market cap $2.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BGLC ranks #949 in composite RQD confidence.

Q: How does BGLC compare to ADVB and ACON in the Health Care sector?

Within the Health Care sector (Medical Specialities), BGLC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 14.6%, and ROIC of -35.0%. By comparison, ADVB (Advanced Biomed Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -9.1%, cap $4.4M) and ACON (Aclarion Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, BGLC leads on earnings multiple (N/A) while ADVB leads on capital efficiency (-9.1% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for BGLC?

Per BGLC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737523), BioNexus Gene Lab Corp generated $7.4M in revenue (-21.9% YoY), -$3.0M in net income, and -$1.9M in free cash flow against $9.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is BGLC trading relative to its 50-day, 200-day, and 52-week technical levels?

BGLC last traded at $0.98 (-7.79% on volume of 4,147 shares), positioning the stock -27.41% below its 50-day simple moving average ($1.35) and -50.00% below its 200-day simple moving average ($1.96). Across its 52-week range of $0.88 to $5.67, BGLC sits at the 2.1% percentile with a 14-day RSI of 24.5 (OVERSOLD (<32)) and an implied next-earnings move of ±10.6% ($1.00 to $1.08).

Q: When is BGLC's next earnings date?

Based on SEC filing cadence, BioNexus Gene Lab Corp (BGLC)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is BGLC stock expected to move on earnings?

Volatility modeling currently projects a ±10.6% event move for BGLC, spanning a range between $1 and $1.08.

$0.98 -7.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.96

BioNexus Gene Lab Corp (BGLC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $2.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.96 (-1.59%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BGLC)Realized 20D OHLCV Swing Band: ±10.6%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY BGLC SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 24.5 (OVERSOLD (<32))

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 14.6% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.29-7% Next Q

Q2 (-2Q)

Grade E$1.20-0.8% Next Q

Q3 (-1Q)

Grade E$1.19-17.6% Next Q

Current

Grade E$0.98-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BGLC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BGLC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.35) and Max Pain ($1.03) forces dealer call-delta covering toward $5.95.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BGLC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BGLC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±10.6% Swing Band

±$0.10 Expected Swing

MODEL EARNINGS SETUP GAUGE

BGLC Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: -21.9%

Model Bullish Setup (30/100)Model Risk Weight (70/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$7.4M	-$3.0M	-$1.9M	14.6%
FY 2024	2024-12-31	$9.5M	-$1.6M	-$2.3M	13.6%
FY 2023	2023-12-31	$9.8M	-$2.6M	-$1.8M	14.6%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BGLC)

✓Walkthrough of BGLC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BGLC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.33%▼ SUPPORT BREAKDOWN

2026-10-30O $0.93H $0.98L $0.88C $0.98VOL 7.5K

RES: $0.98SUP: $1.13SMA50: $1.35SMA200: $1.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BGLC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BGLC Butterfly Map → + Track BGLC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -21.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BGLC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BGLC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BGLC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BGLC)

Health Care Rank #949 of 1016 ⚔️ ADVB vs BGLC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BGLC vs. ADVB, ACON, AMS, SERA)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioNexus Gene Lab Corp (BGLC) ranks #949 by composite RQD confidence (30/100, grade E) and #982 by equity capitalization ($2.9M). Within this direct 5-issuer industry benchmark cohort, BGLC leads on earnings valuation at N/A trailing P/E, while ADVB leads on capital efficiency and profitability with -9.1% ROIC and — gross margin. SERA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BGLC at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BGLC ACTIVE BioNexus Gene Lab Corp	E	30/100	—	14.6%	-35.0%	-7.79%	$2.9M	Benchmark Subject
ADVB Advanced Biomed Inc.	E	32/100	—	—	-9.1%	-11.41%	$4.4M	/advb-vs-bglc →
ACON Aclarion Inc.	E	24/100	—	9.0%	-35.0%	-3.43%	$5.7M	/acon-vs-bglc →
AMS American Shared Hospital Services	E	29/100	—	18.0%	-13.8%	-5.26%	$8.4M	/ams-vs-bglc →
SERA Sera Prognostics Inc. (Class A)	D-	40/100	—	-30.0%	-35.0%	+1.48%	$81.3M	/sera-vs-bglc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001737523

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioNexus Gene Lab Corp (BGLC) reported GAAP revenue of $7.4M (-21.9% vs. FY2024 revenue of $9.5M , and -24.0% cumulative change since FY2023) , GAAP net income of -$3.0M, operating cash flow of -$1.8M, and free cash flow of -$1.9M (+19.2% YoY). On the balance sheet, BGLC closed FY2025 with $9.3M in total assets against $0 in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$7.4M	-$3.0M	-$1.8M	-$1.9M	$9.3M	—
FY2024 (FY)	2024-12-31	$9.5M	-$1.6M	-$2.1M	-$2.3M	$10.4M	—
FY2023 (FY)	2023-12-31	$9.8M	-$2.6M	-$1.8M	-$1.8M	—	—

3. BGLC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BGLC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BioNexus Gene Lab Corp (NASDAQ: BGLC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.98 (-7.79% 1D, market cap $2.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BGLC ranks #949 in composite RQD confidence.

How does BGLC compare to ADVB and ACON in the Health Care sector?

Within the Health Care sector (Medical Specialities), BGLC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 14.6%, and ROIC of -35.0%. By comparison, ADVB (Advanced Biomed Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -9.1%, cap $4.4M) and ACON (Aclarion Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, BGLC leads on earnings multiple (N/A) while ADVB leads on capital efficiency (-9.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BGLC?

Per BGLC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737523), BioNexus Gene Lab Corp generated $7.4M in revenue (-21.9% YoY), -$3.0M in net income, and -$1.9M in free cash flow against $9.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BGLC trading relative to its 50-day, 200-day, and 52-week technical levels?

BGLC last traded at $0.98 (-7.79% on volume of 4,147 shares), positioning the stock -27.41% below its 50-day simple moving average ($1.35) and -50.00% below its 200-day simple moving average ($1.96). Across its 52-week range of $0.88 to $5.67, BGLC sits at the 2.1% percentile with a 14-day RSI of 24.5 (OVERSOLD (<32)) and an implied next-earnings move of ±10.6% ($1.00 to $1.08).